Title |
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
|
---|---|
Published in |
Annals of Hematology, September 2018
|
DOI | 10.1007/s00277-018-3469-4 |
Pubmed ID | |
Authors |
David Cella, Jan McKendrick, Amber Kudlac, Antonio Palumbo, Abderrahim Oukessou, Ravi Vij, Teresa Zyczynski, Catherine Davis |
Abstract |
Treatment of relapsed/refractory multiple myeloma (RRMM) aims to prolong survival while maintaining health-related quality of life (HRQoL) by managing disease-related symptoms and complications-one of the most frequent and debilitating being bone pain. In the ELOQUENT-2 study (NCT01239797), which evaluated the addition of elotuzumab to lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone, pain and HRQoL were assessed in patients with relapsed/refractory disease using the Brief Pain Inventory-Short Form (BPI-SF) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 module (QLQ-C30) and myeloma-specific module (QLQ-MY20). Mean baseline pain scores were low and remained so throughout treatment with both regimens; mean HRQoL scores did not change substantially from baseline. A significantly higher proportion of patients with objective response than without had clinically meaningful improvements in worst pain over two consecutive treatment cycles (29 versus 12%; p < 0.001). Patients with very good partial response (VGPR) or better reported reduced scores for pain severity and worst pain; those with progressive disease reported increased scores for these domains and pain interference. These findings show that previously reported improvements in progression-free survival and response rate with elotuzumab are achieved without detriment to HRQoL, which is maintained over time. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 49 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 12% |
Researcher | 6 | 12% |
Other | 5 | 10% |
Student > Ph. D. Student | 3 | 6% |
Student > Master | 3 | 6% |
Other | 2 | 4% |
Unknown | 24 | 49% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 18% |
Nursing and Health Professions | 6 | 12% |
Biochemistry, Genetics and Molecular Biology | 4 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Economics, Econometrics and Finance | 1 | 2% |
Other | 3 | 6% |
Unknown | 25 | 51% |